Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily budesonide suppository vs budesonide foam in acute ulcerative proctitis
2016-001921-15Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in ulcerative proctitis (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of clinical remission. Started Dec 2016; status: completed.
02
Drugs
budesonide
03
Conditions
ulcerative proctitis
Beyond the preview
Go deeper on 2016-001921-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001921-15.